company background image

Insmed NasdaqGS:INSM Stock Report

Last Price


Market Cap







15 Aug, 2022


Company Financials +
INSM fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health3/6

INSM Stock Overview

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.

Insmed Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Insmed
Historical stock prices
Current Share PriceUS$27.40
52 Week HighUS$34.44
52 Week LowUS$16.41
1 Month Change18.46%
3 Month Change27.44%
1 Year Change19.70%
3 Year Change62.32%
5 Year Change128.72%
Change since IPO-83.39%

Recent News & Updates

Aug 04

Insmed rises 16% on better-than-expected Q2 result

Insmed (NASDAQ:INSM) is trading 16% higher after the company reported Q2 result that beat estimates, helped by higher sales of lung disease treatment, Arikayce. Arikayce net sales were $47.2M in the U.S., $15.8M in Japan, and $2.2M in Europe and rest of world. Q2 GAAP EPS of -$0.80 beats by $0.09, while revenue rose 43.6% to $65.2M, and beats by $6.28M. The company continues to expect full-year global revenues for Arikayce to increase at least 30% year over year from 2021 and expects that its cash on hand will support its ongoing business into 2024. Cost of product revenues rose 52% Y/Y to $16.4M.

Shareholder Returns

INSMUS BiotechsUS Market

Return vs Industry: INSM exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: INSM exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is INSM's price volatile compared to industry and market?
INSM volatility
INSM Average Weekly Movement10.0%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: INSM's weekly volatility (10%) has been stable over the past year.

About the Company

1988613Will Lewis

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.

Insmed Incorporated Fundamentals Summary

How do Insmed's earnings and revenue compare to its market cap?
INSM fundamental statistics
Market CapUS$3.27b
Earnings (TTM)-US$415.96m
Revenue (TTM)US$221.21m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INSM income statement (TTM)
Cost of RevenueUS$52.06m
Gross ProfitUS$169.15m
Other ExpensesUS$585.11m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-3.47
Gross Margin76.47%
Net Profit Margin-188.04%
Debt/Equity Ratio1,772.1%

How did INSM perform over the long term?

See historical performance and comparison